Arbutus Biopharma
ABUS
48 hedge funds and large institutions have $115M invested in Arbutus Biopharma in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 8 closing their positions.
88% more capital invested
Capital invested by funds: $61.1M → $115M (+$54M)
21% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 14
7% more call options, than puts
Call options by funds: $880K | Put options by funds: $819K
6% less funds holding
Funds holding: 51 → 48 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| 1 |
QF
QVT Financial
New York
|
+$62.6M |
| 2 |
AC
Armistice Capital
New York
|
+$3.88M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$198K |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$172K |
| 5 |
Renaissance Technologies
New York
|
+$148K |
Top Sellers
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.16M |
| 2 |
HM
HealthCor Management
New York
|
-$1.01M |
| 3 |
IGIM
I.G. Investment Management
Winnipeg,
Manitoba, Canada
|
-$870K |
| 4 |
SCM
Suffolk Capital Management
New York
|
-$496K |
| 5 |
Millennium Management
New York
|
-$430K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TC
51
TFS Capital
West Chester,
Pennsylvania
| – | -$107K | -30,860 | Closed |
|
|
SLG
52
Stanley-Laman Group
Berwyn,
Pennsylvania
| – | -$90K | -25,722 | Closed |
|
|
DCM
53
Dialectic Capital Management
Norwalk,
Connecticut
| – | -$87K | -25,000 | Closed |
|
54
JP Morgan Chase
New York
| – | -$6K | -1,400 | Closed |
|
|
IA
55
IFP Advisors
Tampa,
Florida
| – | -$391 | -100 | -91% |
|
ABUS Hedge Fund Activity: Q3 2016 in Review
48 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2016, worth a combined $115M — up 88% from $61.1M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ABUS and 5 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 17 added.
The largest buyer was QVT Financial, opening a new position worth an estimated $62.6M. The largest seller was Sabby Management, cutting an estimated $1.16M.
- 48 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2016, down from 51 in Q2 2016.
- Funds reported $115M of Arbutus Biopharma stock for Q3 2016, up 88% quarter-over-quarter.
- 5 funds opened new Arbutus Biopharma positions in Q3 2016 and 8 closed out, a net change of -3 holders.
- The largest Arbutus Biopharma buyer in Q3 2016 was QVT Financial, an estimated $62.6M added.
- The largest Arbutus Biopharma seller in Q3 2016 was Sabby Management, an estimated $1.16M sold.
Based on aggregated 13F filings for Q3 2016.